Sanofi Targets 18 Drug Launches From 2012 To 2015
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Management highlighted several near-term product launch opportunities during a year-end sales and earnings call in an attempt to assure investors business goes on after Plavix, Avapro patent expirations.
You may also be interested in...
Teva’s Generic Irbesartan Deserves 180-Day Exclusivity Because Of Review Delays, FDA Says
Lupin Pharmaceuticals had filed a citizen petition arguing that Teva was not entitled to the first-mover 180-day exclusivity because it failed to get tentative approval within 30 months, but FDA said that it had changed its criteria and requested additional testing.
More Insulin Innovation To Come, Says Novo CEO Sorensen
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
After The Patent Cliff, "New" Sanofi Will Deliver Steady, Modest, Growth
Sanofi is through the worst of its patent cliff and can deliver sales growth of at least 5% per year, on average, between 2012 and 2015, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts. And if 5% is a far cry from the double-digit pharma growth of yesteryear, investors may take heart from higher earnings growth, thanks in large part to an additional €2 billion ($2.8 billion) worth of cost savings and pared down R&D spend – and the promise of a higher dividend.